- Details
- In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...
|
- Details
- Alicia Morgans converses with Neeraj Agarwal about the ongoing phase III Contact-02 Trial, designed for patients with metastatic castrate-resistant prostate cancer (CRPC) who show disease progression on a novel hormonal therapy or androgen receptor inhibitor. Patients eligible for this trial should have measurable disease, which may include extra pelvic lymphadenopathy or visceral metastasis. Dr....
|
- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
- Details
- Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...
|
- Details
- Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...
|
- Details
- Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the impor...
|
- Details
- Alicia Morgans interviews Karim Fizazi to discuss his presentation on the CYPIDES Phase I-II trial. The trial focuses on ODM-208, a CYP11 inhibitor developed with Orion, aimed at treating men with advanced prostate cancer who have exhausted conventional therapies and exhibit androgen receptor mutations. Dr. Fizazi explains that the compound targets the precursor enzymes for various steroids, there...
|
- Details
- Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...
|
- Details
- Philip Koo and Alicia Morgans discuss the evolving role of nuclear medicine in the multidisciplinary care of patients receiving radium-223 for metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Koo advocates for the emergence of "nuclear oncology" as the fourth pillar in comprehensive cancer programs, emphasizing the need for enhanced communication and collaboration among medical oncologi...
|
- Details
- In this conversation, Fred Saad and Alicia Morgans discuss treatment sequencing in terms of Radium-223 when treating a minimally symptomatic patient or a maximally symptomatic patient. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Centre (CHUM), Director, Prostate Cancer Research,...
|
